DK1695714T3 - Genetisk manipuleret herpesvirus til behandling af tumorer - Google Patents

Genetisk manipuleret herpesvirus til behandling af tumorer

Info

Publication number
DK1695714T3
DK1695714T3 DK06009428T DK06009428T DK1695714T3 DK 1695714 T3 DK1695714 T3 DK 1695714T3 DK 06009428 T DK06009428 T DK 06009428T DK 06009428 T DK06009428 T DK 06009428T DK 1695714 T3 DK1695714 T3 DK 1695714T3
Authority
DK
Denmark
Prior art keywords
tumors
treatment
genetically engineered
herpes virus
engineered herpes
Prior art date
Application number
DK06009428T
Other languages
English (en)
Inventor
Ralph Weichselbaum
Bernard Roizman
Richard Whitley
Original Assignee
Arch Dev Corp
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp, Uab Research Foundation filed Critical Arch Dev Corp
Application granted granted Critical
Publication of DK1695714T3 publication Critical patent/DK1695714T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK06009428T 1999-02-05 2000-02-04 Genetisk manipuleret herpesvirus til behandling af tumorer DK1695714T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24474899A 1999-02-05 1999-02-05
PCT/US2000/002814 WO2000045853A2 (en) 1999-02-05 2000-02-04 Treatment of tumors with genetically engineered herpes virus

Publications (1)

Publication Number Publication Date
DK1695714T3 true DK1695714T3 (da) 2008-11-10

Family

ID=22923971

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06009428T DK1695714T3 (da) 1999-02-05 2000-02-04 Genetisk manipuleret herpesvirus til behandling af tumorer

Country Status (10)

Country Link
US (3) US20030207829A9 (da)
EP (2) EP1695714B1 (da)
JP (1) JP4623832B2 (da)
AT (2) ATE402713T1 (da)
AU (2) AU772471B2 (da)
CA (1) CA2361892C (da)
DE (2) DE60027870T2 (da)
DK (1) DK1695714T3 (da)
ES (2) ES2263454T3 (da)
WO (1) WO2000045853A2 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
NZ550861A (en) 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7264814B2 (en) * 2001-05-09 2007-09-04 M's Science Corporation Composition and method for treating cancer using herpes virus
AU2003216502B2 (en) * 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US7501126B2 (en) 2002-10-07 2009-03-10 The University Of Chicago Targeting of herpes simplex virus to specific receptors
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
CA2687301C (en) * 2007-05-09 2016-08-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
EP2307033A4 (en) * 2008-05-29 2012-06-13 Gen Hospital Corp USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
CA2989157A1 (en) * 2015-06-11 2016-12-15 University Of Miami Cancer treatment and diagnosis
RU2751236C2 (ru) * 2016-04-22 2021-07-12 Иммвира Ко., Лимитед КОНСТРУИРОВАНИЕ ОБЛИГАТНОГО ВЕКТОРА НА ОСНОВЕ ОНКОЛИТИЧЕСКИХ ВИРУСОВ ПРОСТОГО ГЕРПЕСА (oHSV) И КОНСТРУКЦИИ ДЛЯ ТЕРАПИИ РАКА
TWI666321B (zh) * 2017-10-23 2019-07-21 大陸商深圳市亦諾微醫藥科技有限公司 用於癌症治療的溶瘤性單純皰疹病毒（ｏＨＳＶ）專性載體及其建構體的建構
KR101974169B1 (ko) 2018-08-10 2019-04-30 의료법인 성광의료재단 재조합 단순 헤르페스 바이러스 및 이의 제조방법
US20220296702A1 (en) * 2019-08-16 2022-09-22 Immvira Co., Limited Pharmaceutical compositions comprising oncolytic herpes simplex virus for systemic administration
AU2020405068A1 (en) 2019-12-18 2022-07-07 Stinginn Llc Substituted 1,2, 4-triazoles and methods of use
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
JP7235334B2 (ja) * 2020-11-26 2023-03-08 イムヴィラ・カンパニー・リミテッド 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築
IL303121A (en) * 2020-12-04 2023-07-01 Immvira Co Ltd Oncolytic herpes simplex viruses type 1 for the treatment of brain tumors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5068192A (en) * 1986-01-27 1991-11-26 Prutech Research And Development Partnership Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence
US4999296A (en) * 1986-04-29 1991-03-12 Novagene, Inc. Thymidine kinase negative insertion mutants of pseudorabies virus and methods for the production of same
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5360893A (en) * 1992-07-20 1994-11-01 University Of Colorado Foundation, Inc. DNA sequences encoding proteins used to elicit and detect programmed cell death
US5593879A (en) * 1993-01-15 1997-01-14 Massachusetts Institute Of Technology Cell death genes of Drosophila melanogaster and vertebrate analogs
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
ATE241994T1 (de) * 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
CA2200633A1 (en) * 1997-03-21 1998-09-21 Yuman Fong Rapid production of autologous tumor vaccines

Also Published As

Publication number Publication date
EP1695714A1 (en) 2006-08-30
EP1150696A2 (en) 2001-11-07
DE60027870T2 (de) 2006-12-28
AU2980000A (en) 2000-08-25
EP1695714B1 (en) 2008-07-30
US20130039890A1 (en) 2013-02-14
WO2000045853A3 (en) 2001-05-31
AU2004203458A1 (en) 2004-08-26
US20030207829A9 (en) 2003-11-06
US8772261B2 (en) 2014-07-08
US8318691B2 (en) 2012-11-27
JP4623832B2 (ja) 2011-02-02
WO2000045853A2 (en) 2000-08-10
US20020019362A1 (en) 2002-02-14
ATE402713T1 (de) 2008-08-15
EP1150696B1 (en) 2006-05-10
DE60039730D1 (de) 2008-09-11
ATE325615T1 (de) 2006-06-15
US20110002890A1 (en) 2011-01-06
JP2002536347A (ja) 2002-10-29
ES2310382T3 (es) 2009-01-01
DE60027870D1 (de) 2006-06-14
AU2004203458B2 (en) 2007-05-17
CA2361892A1 (en) 2000-08-10
ES2263454T3 (es) 2006-12-16
CA2361892C (en) 2010-05-25
AU772471B2 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
DE60039730D1 (de) Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
DE69834827D1 (en) Phototherapeutische systeme
CY2016021I1 (el) Στελεχη ιων για την ογκολυτικη θεραπεια του καρκινου
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
EP0725106A3 (en) Radiation curable compositions
EP1028757A4 (en) RADIOACTIVE EMOLIZING COMPOSITIONS
NO20005342D0 (no) Belysningsapparat for fotodynamisk terapi
DK0768885T3 (da) Fremgangsmåde til inhibering af cancermetastase ved oral administration af oplöselig modificeret citruspectin
AU7380500A (en) Methods for treating tumors using neutron therapy
TR199802676A3 (tr) Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem.
DK0942754T3 (da) Konjugater anvendelige til behandlingen af prostatacancer
ATE316134T1 (de) Zusammensetzung mit alpha-glycosylceramid zur stärkung zellulärer immunogenität
ATE397458T1 (de) Neue heilmittel für krebs
DK0725637T3 (da) Parenteralt busulfan til behandling af malign sygdom
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
ATE306281T1 (de) Antivirales mittel in kombination mit strahlentherapie zur verwendung in der behandlung von krebs
MXPA02007271A (es) Compuestos de tipo pirrol, composiciones que los contienen, y metodos para el tratamiento de cancer o enfermedades virales.
GB2378948B (en) Novel compounds for modulating cell proliferation
GB0120318D0 (en) System and method for optimizing radiation treatment with an intensity modulating multi-leaf collimator
FI960658A7 (fi) Uudet bis-naftalimidit syövän hoitamiseksi
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
ATE368649T1 (de) Cyanoguanidin prodrugs